+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Medulloblastoma - Pipeline Review, H1 2020

  • ID: 5130303
  • Drug Pipelines
  • June 2020
  • Region: Global
  • 380 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aettis Inc
  • CDG Therapeutics Inc
  • IMPACT Therapeutics Inc
  • Mana Therapeutics Inc
  • Nascent Biotech Inc
  • Pfizer Inc
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H1 2020, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 10, 14, 1, 2, 16 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 7 and 3 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aettis Inc
  • CDG Therapeutics Inc
  • IMPACT Therapeutics Inc
  • Mana Therapeutics Inc
  • Nascent Biotech Inc
  • Pfizer Inc
  • MORE
  • Introduction
  • Medulloblastoma - Overview
  • Medulloblastoma - Therapeutics Development
  • Medulloblastoma - Therapeutics Assessment
  • Medulloblastoma - Companies Involved in Therapeutics Development
  • Medulloblastoma - Drug Profiles
  • Medulloblastoma - Dormant Projects
  • Medulloblastoma - Discontinued Products
  • Medulloblastoma - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Medulloblastoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Medulloblastoma - Pipeline by Aettis Inc, H1 2020
  • Medulloblastoma - Pipeline by Bayer AG, H1 2020
  • Medulloblastoma - Pipeline by Biogenera SpA, H1 2020
  • Medulloblastoma - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Medulloblastoma - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Medulloblastoma - Pipeline by CDG Therapeutics Inc, H1 2020
  • Medulloblastoma - Pipeline by Curis Inc, H1 2020
  • Medulloblastoma - Pipeline by Dalriada Therapeutics Inc, H1 2020
  • Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H1 2020
  • Medulloblastoma - Pipeline by Dracen Pharmaceuticals Inc, H1 2020
  • Medulloblastoma - Pipeline by Eli Lilly and Co, H1 2020
  • Medulloblastoma - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2020
  • Medulloblastoma - Pipeline by Immunomic Therapeutics Inc, H1 2020
  • Medulloblastoma - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Medulloblastoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3
  • Aettis Inc
  • Bayer AG
  • Biogenera SpA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • CDG Therapeutics Inc
  • Curis Inc
  • Dalriada Therapeutics Inc
  • DelMar Pharmaceuticals Inc
  • Dracen Pharmaceuticals Inc
  • Eli Lilly and Co
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Immunomic Therapeutics Inc
  • IMPACT Therapeutics Inc
  • Janpix Inc
  • Lumos Pharma Inc
  • MacroGenics Inc
  • Mana Therapeutics Inc
  • Midatech Pharma Plc
  • MimiVax LLC
  • Moleculin Biotech LLC
  • Nascent Biotech Inc
  • Novartis AG
  • Oncoheroes Biosciences Inc
  • Ono Pharmaceutical Co Ltd
  • Oxurion NV
  • Pfizer Inc
  • Progenics Pharmaceuticals Inc
  • Sapience Therapeutics Inc
  • Senhwa Biosciences Inc
  • Shionogi & Co Ltd
  • Stemsynergy Therapeutics Inc
  • TheraBiologics Inc
  • VBI Vaccines Inc
  • Vyriad Inc
  • Y-mAbs Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll